CN1303384A - 吡咯并[1,2－a]吡嗪sPLA2抑制剂 - Google Patents

吡咯并[1,2－a]吡嗪sPLA2抑制剂 Download PDF

Info

Publication number
CN1303384A
CN1303384A CN99806627A CN99806627A CN1303384A CN 1303384 A CN1303384 A CN 1303384A CN 99806627 A CN99806627 A CN 99806627A CN 99806627 A CN99806627 A CN 99806627A CN 1303384 A CN1303384 A CN 1303384A
Authority
CN
China
Prior art keywords
iii
ethyl
pyrazin
compound
glycolic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99806627A
Other languages
English (en)
Chinese (zh)
Inventor
大谷光昭
富士雅弘
冈田哲夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CN1303384A publication Critical patent/CN1303384A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN99806627A 1998-03-31 1999-03-31 吡咯并[1,2－a]吡嗪sPLA2抑制剂 Pending CN1303384A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP8599798 1998-03-31
JP85997/1998 1998-03-31
JP244735/1998 1998-08-31
JP24473598 1998-08-31

Publications (1)

Publication Number Publication Date
CN1303384A true CN1303384A (zh) 2001-07-11

Family

ID=26427020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99806627A Pending CN1303384A (zh) 1998-03-31 1999-03-31 吡咯并[1,2－a]吡嗪sPLA2抑制剂

Country Status (11)

Country Link
US (1) US6407104B1 (https=)
EP (1) EP1066290A1 (https=)
JP (1) JP4412521B2 (https=)
KR (1) KR20010042307A (https=)
CN (1) CN1303384A (https=)
AU (1) AU3054399A (https=)
BR (1) BR9909345A (https=)
CA (1) CA2326522A1 (https=)
HU (1) HUP0102981A3 (https=)
NO (1) NO20004881L (https=)
WO (1) WO1999051605A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105622616A (zh) * 2016-02-25 2016-06-01 上海雅本化学有限公司 一种4-氯吡咯并嘧啶的制备方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346334A1 (en) 1998-10-14 2000-04-20 Shionogi & Co., Ltd. Composition for treating or preventing ischemia reperfusion injury
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環系化合物
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
US6756376B1 (en) 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
WO2002012249A2 (en) * 2000-08-04 2002-02-14 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
TWI314457B (https=) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
DE10155727A1 (de) * 2001-11-13 2003-05-28 Morphochem Ag Serin Protease Inhibitoren
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DK1910384T3 (da) * 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP4378924A4 (en) * 2021-09-17 2025-09-03 Mitsui Chemicals Inc PROCESS FOR PRODUCING A (METH)ACRYLAMIDE COMPOUND

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
PL180523B1 (pl) 1994-04-01 2001-02-28 Eli Lilly & Co Nowy zwiazek, pochodna 1H-indolo-3-glioksylamidu i srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
JPH10505584A (ja) 1994-07-21 1998-06-02 イーライ・リリー・アンド・カンパニー インドリジンｓＰＬＡ▲下２▼インヒビター
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US6214876B1 (en) * 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
AU1289797A (en) 1995-12-13 1997-07-03 Eli Lilly And Company Naphthyl acetamides as spla2 inhibitors
KR19990072111A (ko) 1995-12-13 1999-09-27 피터 지. 스트링거 Spla2 억제제인 나프틸 글리옥스아미드
JP2001503055A (ja) 1996-10-30 2001-03-06 イーライ・リリー・アンド・カンパニー 置換三環化合物群
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
TW455581B (en) 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105622616A (zh) * 2016-02-25 2016-06-01 上海雅本化学有限公司 一种4-氯吡咯并嘧啶的制备方法

Also Published As

Publication number Publication date
KR20010042307A (ko) 2001-05-25
HUP0102981A3 (en) 2002-10-28
HUP0102981A2 (hu) 2002-01-28
NO20004881L (no) 2000-11-28
US6407104B1 (en) 2002-06-18
WO1999051605A1 (en) 1999-10-14
AU3054399A (en) 1999-10-25
JP2002530268A (ja) 2002-09-17
JP4412521B2 (ja) 2010-02-10
CA2326522A1 (en) 1999-10-14
NO20004881D0 (no) 2000-09-28
EP1066290A1 (en) 2001-01-10
BR9909345A (pt) 2000-12-12

Similar Documents

Publication Publication Date Title
CN1303384A (zh) 吡咯并[1,2－a]吡嗪sPLA2抑制剂
CN1255403C (zh) 用作磷酸二酯酶抑制剂的β－咔啉衍生物
KR101891933B1 (ko) B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 피리다존 및 트라이아진온
JP6568106B2 (ja) Ｂ型肝炎ウイルス感染症の治療及び予防のための新規ジヒドロキノリジノン類
AU2003258576B2 (en) Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors
CN100343253C (zh) 用作HIV整合酶抑制剂的四氢－4H－吡啶并[1,2－а]嘧啶和相关化合物
JP4351053B2 (ja) ジヒドロキシピリミジンカルボキサミド系ｈｉｖインテグラーゼ阻害薬
CN1694708A (zh) TGFβ的抑制剂
KR20140143160A (ko) B형 간염 바이러스 감염의 치료 및 예방을 위한 신규한 4-메틸-다이하이드로피리미딘
JP2018510208A (ja) 縮合環化合物、医薬組成物およびその使用
AU2002334205A1 (en) Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
CN101061111A (zh) Dna－pk抑制剂
CN1409711A (zh) 用作hiv逆转录酶抑制剂的稠合的二氮萘化合物
CN1378544A (zh) 取代的唑系化合物
CN1302300A (zh) 吡咯并[1,2－b]哒嗪sPLA2抑制剂
CN1160402A (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1231472C (zh) 嘧啶无环核苷衍生物、其制备方法及其用途
CN101039938A (zh) 作为flap抑制剂的二苯基取代的烷烃
US9090597B2 (en) Pyrazolone derivatives as PDE4 inhibitors
CN1802375A (zh) 用于治疗炎性疾病的β－咔啉
CN1780836A (zh) 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物
CN1642954A (zh) 用作hiv逆转录酶抑制剂的三环型2－嘧啶酮化合物
CN1206230C (zh) 4－吡啶基－和2,4－嘧啶基－取代的吡咯衍生物及其在药学中的应用
CN1505624A (zh) 哌嗪子基衍生物及其作为pde4抑制剂的用途
WO2022087422A9 (en) Pyrrolidine-3-carboxamide derivatives and related uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1080931

Country of ref document: HK